This page shows the latest metreleptin news and features for those working in and with pharma, biotech and healthcare.
Aegerion’s rare disease drug approved. Specialist pharma company Aegerion has gained European approval for Myalepta (metreleptin) for the ultra-rare condition, lipodystrophy.
Another orphan drug, Novelion’s Myalepta (metreleptin) also received a positive opinion, for the treatment of leptin deficiency, while Lundbeck and Otsuka’s Rxulti (brexpiprazole) was recommended for the treatment of
For example, Amgen's Blincyto (blinatumomab) for a rare form of leukaemia has been priced at $178, 000 a year, while AZ's Myalept (metreleptin) for the ultra-rare metabolic disorder
Meanwhile, AZ also said it is selling Myalept (metreleptin), an approved drug for generalised lipodystrophy, to Aegerion Pharmaceuticals.
Epanova gets green light to reduce high levels of fat in the blood
Myalept (metreleptin) - a recombinant form of the hormone leptin that was unsuccessfully studied as an obesity therapy by Bristol-Myers Squibb (BMS) - has been approved as a replacement therapy for patients ... The company stressed that metreleptin is
More from news
Approximately 3 fully matching, plus 10 partially matching documents found.
Option. 444. AstraZeneca / Aegerion. Myalet (metreleptin) injection for leptin deficiency.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...